RAS-Targeted Drug Discovery Summit 2019

RAS-Targeted Drug Discovery Summit 2019 is organized by Hanson Wade and will be held from Sep 17 - 19, 2019 at Omni Parker House, Boston, Massachusetts, United States of America.

Description:
Following the exciting clinical progression from Amgen and Mirati Therapeutics, at a time when there is a translational opportunity to finally “drug” RAS proteins with clinically meaningful success, the 1st RAS- Targeted Drug Discovery Summit has been established to unite large pharma, biotech and academic KOLs who are striving to capitalize on the therapeutic potential of targeting RAS.

With RAS mutations prevalent in approximately 30% of all cancers diagnosed, the clinical, patient outcome and commercial opportunity are tremendous. As such, the RAS- Targeted Drug Discovery Summit will be dedicated to helping oncology drug discovery and development professionals understand the cutting edge dynamics and function of RAS biology, identify and validate druggable target sites and improve the preclinical predictability of patient-derived and disease-specific RAS models.

With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the 1st RAS- Targeted Drug Discovery Summit – the only industry and translational focused conference dedicated to advancing pioneering RAS biology and drug discovery into successful clinical candidates.

Pre-Conference Workshop Day

Workshop A - Tuesday, September 17 (10:30 am - 13:00 pm)

Exploring Current Caveats and Future Challenges in Understanding Oncogenic RAS Structure and Function: Influence of the Mutations

Workshop Leader:
Tatu Pantsar
Marie Sk?odowska-Curie Fellow
University of Tübingen

Workshop B - Tuesday, September 17 (14.00pm - 16.30pm)

Empowering Anti-RAS Strategies: From Mouse Models to Clinical Research

Workshop Co-Leaders:
Chiara Ambrogio
Senior Scientist
Dana-Farber Cancer Institute

Kenneth Westover
Associate Professor
UT Southwestern Medical Center

Time: 12:30 pm - 9:00 pm

Additional details will be posted as soon as they are available.